• A Novel Next Generation 5-aminosalicylic acid (5-ASA) Molecular Conjugate
  • Designed for Slow Sustained Release of the Bioactives at the Target Site (Intestine/Colon)
  • Host Intestinal Enzyme Mediated Release of the Actives; 5-ASA, Eicosapentaenoic Acid (EPA) and Caprylic Acid (CPA) at the Target Site
  • All the Released Actives 5-ASA, EPA and CPA, expected to have Beneficial Synergistic Pharmacological Effects
  • Expected to be Clinically more Efficacious than the Commercial Formulations of 5-ASA/ Sulphasalazine
  • Safer than Suphasalazine and 5-ASA formulations; Reduced Systemic Exposure to 5-ASA, N-Acetyl 5-ASA. No Systemic Exposure to Sulphapyridine
  • Preclinical Work Nearing Completion, Ready for IND Filing and Clinical Development
  • Regulatory: 505(b)(2) Pathway
  • Intellectual Property: Issued U.S Patent, Australia Patent, Singapore Patent. National Stage Filings were filed in 12 countries with their respective PTO’s.

  • A Novel Molecular Conjugate of Eslicarbazepine and Eicosapentaenoic acid (EPA)
  • Host Enzyme Mediated Release of the Bioactives
  • CLX-104 could potentially offer to reduce the incidence of drug resistance in epilepsy due to its synergistic pharmacological effects with EPA for patients who are on treatment with various drugs.
  • Clinically, extant literature evidence on EPA supports theproficient Pharmacological Effects in Controlling Seizures and Neuronal Stabilization (DeGiorgio et al., 2014, Schlanger S., et al. 2002; Yuen A.W. et al. 2005)
  • Expected to be Clinically Efficacious than Eslicarbazepine in the treatment of Epilepsy
  • Preclinical Work: Nearing to GLP Tox.
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: Issued U.S Patent. National Stage Filings were filed in 12 countries with their respective PTO’s.

  • A Novel Molecular Conjugate of Valproic acid (VPA) for the treatment of Epilepsy, Bipolar disorder and potential Oncology indications
  • Designed for slow sustained release of the actives
  • Host enzyme mediated release of the actives
  • Enhanced Synergistic Pharmacological effects with improved Efficacy Profile
  • Better Hepatic and Gastric safety profile than VPA alone for approved indications
  • Potential opportunity in oncology considering histone deacetylase inhibitory activity of VPA in combination therapy for various cancer treatments
  • Preclinical studies are ongoing
  • Regulatory: Targeting 505(b)(2) Pathway for Epilepsy 505(b)(1) Pathway for Oncology
  • Intellectual Property: U.S Patent Pending. National Stage Filings were filed in 12 countries with their respective PTO’s.

  • A Novel Glycerol Molecular Conjugate of MonoMethylFumarate (MMF) for the treatment of Multiple Sclerosis and Psoriasis
  • A Novel Ester Conjugate of MMF and EPA for the treatment of Multiple Sclerosis and Psoriasis
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile and also Dose Dependent Flushing of DimethylFumarate
  • Pre-Clinical: Completion and Currently at IND filing stage
  • Regulatory: 505(b)(2) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s

  • A Novel Molecular Conjugate of L-DOPA for the treatment of Parkinson’s disease
  • Novel Molecular Conjugate of Carbidopa for the treatment of Parkinson’s disease
  • Designed for slow sustained release of the actives. Host enzyme mediated release of the actives
  • Improved pharmacokinetic profile than the current L-DOPA formulations
  • Enhanced efficacy offered through synergistic pharmacology of bioactives released from the molecular conjugate
  • Intended for both oral and subcutaneous depot administration
  • Preclinical studies are ongoing
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: US Patent Pending. International Patent Applications were filed with WIPO.

  • A Novel Next Generation Halofenate Derivative for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
  • Expected to be more efficacious than the arhalofenate which is currently in Phase III clinical trials
  • Synergistic pharmacological effect from omega-3 Fatty acids as an anti-inflammatory agent as a comorbidity in gout is an auxiliary benefit
  • Designed for slow and sustained release of the actives in the small intestine
  • Regulatory: Targeting 505(b)(1) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s


  • A Novel Salt of Bupivacaine with Gamma Linolenic acid for the treatment of oral mucositis induced pain associated with chemo/radio therapy in head and neck cancer patients
  • A Novel Salt of Bupivacaine with Linoleic acid for the treatment of oral mucositis induced pain associated with chemo/radio therapy in head and neck cancer patients
  • A Novel Salt of Bupivacaine with Lauric acid for the treatment of oral mucositis induced pain associated with chemo/radio therapy in head and neck cancer patients
  • Designed for simple dissociation into bupivacaine and fatty acid molecules (which are GRAS listed)
  • The dissociated bupivacaine and long chain fatty acids have beneficial pharmacological effects Bupivacaine exerts its action as local anesthetic, sustained for longer period of time and the long chain fatty acids released exerts its anti-inflammatory and anti-microbial effects
  • Linoleic acid reported to have anti-microbial activity at 25 mcg/ml against Actinobacillusactinomycetemcomitants, Fusobacterium nucleatum, Streptococcus mutans, Streptococcus gordonii, and Streptococcus sangius(Huang C.B. et al., 2010). The minimum inhibitory concentration for linoleic acid against Porphyromonasgingivalis was 78 mcg/ml (Choi et al., 2013)
  • Pilot in vitro study had shown dissociation of bupivacaine moiety comparable to that of bupivacaine hydrochloride in Grade III Oral Mucositis Patients Saliva
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: US Patent Pending and International Patent Applications were filed with the WIPO

  • A Novel Molecular Conjugate of Diclofenac for the management of Pain in Osteoarthritis, Rheumatoid arthritis and Severe Pain
  • Designed to be stable in the gastric fluid, resulting in reduced NSAID Class Gastric Ulceration
  • Designed to release the active moiety, diclofenac by host intestinal enzyme mediated hydrolysis
  • Safer than the marketed diclofenac formulations
  • CLX-118 demonstrated enhanced PK profile (in terms of Cmax and AUC) in compared to diclofenac sodium salt in rodent studies
  • Enhanced safety and tolerability profile (reduction of the local toxicity in stomach and upper small intestine)
  • Preclinical studies are ongoing
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s

  • A Novel Molecular Conjugate of eicosapentaenoic acid (EPA) for the treatment of familial adenomatous polyposis (FAP)
  • Orphan Drug Indication
  • Designed to be stable in the gastric fluids and targeted to release the active moieties by host intestinal enzyme mediated hydrolysis in the targeted site (colon)
  • Enhanced Efficacy, Safety and Tolerability Profile
  • No Currently Approved Therapy for the Indication
  • Regulatory: Orphan Drug, 505(b)(1) NCE
  • Intellectual Property: Issued US Patent.

  • MSTM-101 has not changed the way metformin works but instead, has discovered and leverages the understanding to develop an improved best-in-class therapeutic product targeted for Diabetics with Comorbidities such as Hypertriglyceridemia or Familial (genetic) Hypertriglyceridemia patients with elevated Cardiovascular Risk
  • This improved profile of MSTM-101 provides both glycemic control and reduction of elevated triglycerides in a specific relative synergy of metformin and EPA on lipid levels in type 2 diabetic patients
  • MSTM-101 is a solid, stable and highly water soluble New Molecular Entity (NME). Dissociates instantaneously in all physiological fluids, to deliver metformin and eicosapentaenoic-D-pantothenate
  • MSTM-101 can be administered orally or parenterally to deliver high plasma levels of the therapeutic equivalent levels of free fatty acids, of EPA at a much lower dosage compared to approved commercial formulations of omega 3 fatty acids
  • Non-Clinical Work: Pre-Formulation and PK studies Completed. IND enabling package will be initiated soon
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: Issued U.S Patent. National Stage Filings in 12 countries were filed with their respective PTO’s

  • MSTM-102 is a solid, stable and highly water soluble New Molecular Entity (NME) for the treatment of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH)
  • Dissociates instantaneously in all physiological fluids, to deliver metformin and eicosapentaenoic-D-pantothenate and PDE5 inhibitor, sildenafil
  • MSTM-102 can be administered orally and has an ability to deliver metformin, PDE5 inhibitor, Pantothenic acid and high plasma levels of the therapeutic equivalent levels of free fatty acids, EPA at a much lower dosage compared to approved commercial formulations of omega 3 fatty acids
  • All the released actives will have synergistic pharmacological effect in controlling lipid metabolism (currently no approved drugs for NAFLD and NASH)
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: US Patent Pending. International Patent Applications were filed with WIPO

  • A Novel Next Generation Fluorinated PyrimidineMolecular Conjugate
  • Designed for Slow Sustained Release of the Bioactives at the Target Site (Intestine/Colon)
  • Host Intestinal Enzyme Mediated Release of the Actives; 5-FU analog and Anti-Proliferative Natural Fatty acids at the Target Site
  • All the Released Actives 5-FU analog and other Fatty Acids, expected to have Beneficial Synergistic Pharmacological Effects
  • Expected to be Clinically more Efficacious than the Commercial Formulations of 5-FU and its related derivatives/analogs
  • Safer than 5-FU formulations and its related derivatives/analogs; Reduced Systemic Exposure to 5-FU resulting in Substantial Reduction of Side effect and Adverse Event Profile in Patients undergoing Chemotherapy
  • Preclinical Studies: Ongoing
  • Regulatory: Targeting 505(b)(2) Pathway
  • Intellectual Property: International Patent Filing.